CII
REGN icon

Capital International Inc’s Regeneron Pharmaceuticals REGN Stock Holding History

Capital International Inc’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$8.2M Buy
13,154
+1,395
+12% +$950K 0.06% 207
2026
Q1 		$9.09M Sell
11,759
-744
-6% -$570K 0.07% 196
2025
Q4 		$9.65M Sell
12,503
-24,867
-67% -$16.9M 0.08% 203
2025
Q3 		$21M Sell
37,370
-33,485
-47% -$18.9M 0.17% 148
2025
Q2 		$37.2M Sell
70,855
-2,356
-3% -$1.31M 0.36% 75
2025
Q1 		$46.4M Buy
73,211
+2,606
+4% +$1.79M 0.56% 50
2024
Q4 		$50.3M Buy
70,605
+6,380
+10% +$5.35M 0.59% 46
2024
Q3 		$67.5M Buy
64,225
+2,983
+5% +$3.32M 0.85% 31
2024
Q2 		$64.4M Buy
61,242
+4,873
+9% +$4.72M 0.86% 34
2024
Q1 		$54.3M Buy
56,369
+2,801
+5% +$2.66M 0.73% 38
2023
Q4 		$47M Buy
53,568
+1,655
+3% +$1.36M 0.73% 36
2023
Q3 		$42.7M Buy
51,913
+8,484
+20% +$6.67M 0.82% 34
2023
Q2 		$31.2M Buy
43,429
+5,730
+15% +$4.42M 0.57% 50
2023
Q1 		$31M Sell
37,699
-1,032
-3% -$778K 0.62% 46
2022
Q4 		$27.9M Sell
38,731
-1,451
-4% -$1.07M 0.6% 45
2022
Q3 		$27.7M Sell
40,182
-41,326
-51% -$26M 0.62% 50
2022
Q2 		$48.2M Sell
81,508
-7,773
-9% -$5.05M 0.67% 49
2022
Q1 		$62.4M Buy
89,281
+57,745
+183% +$36.5M 0.7% 47
2021
Q4 		$19.9M Buy
31,536
+732
+2% +$450K 0.19% 132
2021
Q3 		$18.6M Sell
30,804
-2,356
-7% -$1.46M 0.18% 131
2021
Q2 		$18.5M Sell
33,160
-3,434
-9% -$1.74M 0.17% 135
2021
Q1 		$17.3M Sell
36,594
-3,781
-9% -$1.84M 0.16% 138
2020
Q4 		$19.5M Buy
40,375
+3,161
+8% +$1.71M 0.18% 128
2020
Q3 		$20.8M Buy
37,214
+1,412
+4% +$856K 0.23% 114
2020
Q2 		$22.3M Buy
35,802
+13,558
+61% +$7.7M 0.27% 112
2020
Q1 		$10.9M Buy
+22,244
New +$9.18M 0.18% 111
2019
Q3 		– Sell
-11,446
Closed -$3.58M – 241
2019
Q2 		$3.58M Buy
+11,446
New +$3.81M 0.25% 94

Other funds holding REGN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Nuveen
Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return

Capital International Inc's REGN Position: Q2 2026 in Review

Capital International Inc increased its Regeneron Pharmaceuticals (REGN) stake by 12% in Q2 2026, buying an estimated $950K and bringing the position to 13,154 shares worth $8.2M. The position accounts for 0.06% of the portfolio, ranked #207.

Capital International Inc first reported a position in REGN in Q2 2019 and has held it in 27 quarters since. The position peaked at $67.5M in Q3 2024. 1,332 funds tracked by Wall St. Rank hold REGN as of Q2 2026.

  • Capital International Inc held 13,154 shares of Regeneron Pharmaceuticals worth $8.2M as of Q2 2026.
  • Capital International Inc bought 1,395 Regeneron Pharmaceuticals shares in Q2 2026, an estimated $950K.
  • Regeneron Pharmaceuticals made up 0.06% of Capital International Inc's portfolio in Q2 2026, its #207 holding.
  • Capital International Inc first reported a position in Regeneron Pharmaceuticals in Q2 2019 and has held it in 27 quarters since.
  • Capital International Inc's Regeneron Pharmaceuticals position peaked at $67.5M in Q3 2024.
  • 1,332 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q2 2026.

Based on Capital International Inc's 13F filing for Q2 2026, filed 12 Aug 2026.